Opportunistic infections (OIs) in healthy Okinawan carriers of human T-cell lymphotropic virus type I (HTLV-I) (Meeting abstract).

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Opportunistic infections (OIs) in healthy Okinawan carriers of human T-cell lymphotropic virus type I (HTLV-I) (Meeting abstract).

Proc Annu Meet AM Soc Clin Oncol; 12:A1010 1993. Unique Identifier : AIDSLINE ICDB/94695409
Kaime EM; Ikehara O; Thomas R; Brodine S; Naval Hosp., San Diego, CA 92134

Abstract: Between July 1982 and November 1992, 12 Okinawan healthy carriers (HCs) of HTLV-I admitted to Okinawa Chuba Hospital were identified as having OIs. HC is defined by Shimoyama et al (Br J Haem 79:428-37, 1991) as one seropositive for HTLV-I with less than 4000 absolute lymphs and less than 5% abnormal lymphs in peripheral blood, normal serum calcium and LDH, and no organ involvement with malignant cells. The 12 HCs ranged in age from 29 to 75, median 43; there were 8 males and 4 females. The OIs seen included strongyloidiasis (hyperinfection or severe malabsorption) in 9, pneumocystis and cytomegalovirus pneumonia in 1, disseminated tuberculosis in 1 and actinomycosis pneumonia in 1. PPD was negative in 7 of 8 HCs tested. Serum IgG was low in 1 of 9 HCs tested, IgA and IgM was normal or high in all tested. CD4 lymphocyte range 34-87%, CD8 8-39%, and CD4/8 1.1-11.3. Three HCs died from their OI. Two HCs progressed to acute T-cell leukemia at 34 and 46 mo after initial diagnosis and died soon after. HCs of HTLV-I may have profound immunosuppression that cannot be adequately quantified, but that leads to serious and often fatal opportunistic infections.

Keywords: Actinomycosis/COMPLICATIONS Cytomegalovirus/ISOLATION & PURIF Female Human HTLV-I Infections/*COMPLICATIONS Male Opportunistic Infections/*COMPLICATIONS Pneumonia/COMPLICATIONS/MICROBIOLOGY Pneumonia, Pneumocystis carinii/COMPLICATIONS Strongyloidiasis/COMPLICATIONS Tuberculosis, Pulmonary/COMPLICATIONS ABSTRACT
940228
M9420825

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .